Albini E, Belluco G, Berton M, Schioppacassi G, Ungheri D
Microbiology Laboratory, Zambon Group S.p.A., Bresso, Italy.
Arzneimittelforschung. 1999 Jun;49(6):533-7. doi: 10.1055/s-0031-1300456.
After 30 years of therapeutic use, thiamphenicol glycinate acetylcysteinate (CAS 20192-91-0) is still widely employed in the treatment of upper and lower respiratory tract infections. This is due to its particular characteristic to exert at pulmonary level, either the antibacterial activity of thiamphenicol (CAS 15318-45-3) and the mucolytic activity of N-acetylcysteine (CAS 616-91-1). The aim of this study was to evaluate the present pattern of susceptibility of several clinical isolates to thiamphenicol and the interference of N-acetylcysteine on this parameter. The studies have been performed in vitro. Equimolar concentrations of N-acetylcysteine and even higher concentrations did not interfere with the antibacterial activity of thiamphenicol against Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae. The spectrum of activity of thiamphenicol was similar to that observed in the past and was superior to that of erythromycin and amoxicillin. The activity of thiamphenicol was greater than that of erythromycin against H. influenzae and streptococci and equivalent versus Branhamella catarrhalis. In comparison with amoxicillin the activity of thiamphenicol was higher against H. influenzae and B. catarrhalis and slightly lower against streptococci. The results demonstrate that thiamphenicol maintains its therapeutic value confirming the importance of thiamphenicol glycinate acetylcysteinate in the treatment of respiratory tract infections.
在经过30年的治疗应用后，甘氨酸乙酰半胱氨酸甲砜霉素（CAS 20192-91-0）仍被广泛用于治疗上、下呼吸道感染。这是因为它具有独特的特性，在肺部既能发挥甲砜霉素（CAS 15318-45-3）的抗菌活性，又能发挥N-乙酰半胱氨酸（CAS 616-91-1）的黏液溶解活性。本研究的目的是评估几种临床分离株对甲砜霉素的当前药敏模式以及N-乙酰半胱氨酸对该参数的干扰。研究是在体外进行的。等摩尔浓度的N-乙酰半胱氨酸以及更高浓度的N-乙酰半胱氨酸均未干扰甲砜霉素对肺炎链球菌、化脓性链球菌和流感嗜血杆菌的抗菌活性。甲砜霉素的活性谱与过去观察到的相似，且优于红霉素和阿莫西林。甲砜霉素对流感嗜血杆菌和链球菌的活性大于红霉素，对卡他莫拉菌的活性与之相当。与阿莫西林相比，甲砜霉素对流感嗜血杆菌和卡他莫拉菌的活性更高，对链球菌的活性略低。结果表明，甲砜霉素保持了其治疗价值，证实了甘氨酸乙酰半胱氨酸甲砜霉素在治疗呼吸道感染中的重要性。
